Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC

A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news